FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study

Andries J. Hoitsma¹, Ervin S. Woodle², Daniel Abramowicz³, Pieter Proot⁴ and Yves Vanrenterghem⁵ on behalf of the FTY720 Phase II Transplant Study Group

¹Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, ²Division of Transplantation, University of Cincinnati, Cincinnati, OH, USA, ³Department of Nephrology, Hôpital Erasme, Brussels, Belgium, ⁴Development, Novartis Pharma AG, Basel, Switzerland and ⁵Department of Nephrology, University Hospital Gasthuisberg, Leuven, Belgium

Correspondence and offprint requests to: Andries J. Hoitsma; E-mail: a.hoitsma@nier.umcn.nl

Abstract

Background. FTY720 (fingolimod), a novel immunomodulator, has demonstrated potential for prevention of acute rejection in combination with cyclosporine.

Methods. This study evaluated FTY720 2.5 mg versus mycophenolate mofetil (MMF) in a combination regimen with standard tacrolimus and corticosteroids in de novo renal transplant recipients for the composite efficacy within 6 months of transplantation.

Results. Incidence of treated biopsy-proven acute rejection was 22.9% with FTY720 and 18.5% with MMF. Increased incidence of macular oedema, transient decrease in heart rate and low rate of infections were seen in the FTY720 arm.

Conclusion. FTY720 combined with tacrolimus and steroids did not show a significant therapeutic advantage over MMF for the prevention of acute rejection in de novo renal transplant recipients.

Keywords: FTY720; mycophenolate mofetil; renal transplantation; sphingosine 1-phosphate receptor; tacrolimus

Introduction

FTY720 (fingolimod) is a novel immunomodulator and representative of sphingosine 1-phosphate receptor...
modulators that was developed to address the need for new immunosuppressive drugs that provide adequate efficacy while minimizing drug-related toxicity [1–3]. Phase II studies have demonstrated optimal efficacy and safety of FTY720 up to the doses of 5 mg [2, 4].

This Phase III study compared FTY720 versus mycophenolate mofetil (MMF) in a combination regimen with standard tacrolimus in renal transplant recipients. Recruitment into this study was suspended based on the results of other simultaneous Phase III studies in renal transplantation wherein FTY720 did not show any benefit over the standard of care. Later, this study was discontinued as a part of sponsor decision to terminate the FTY720 clinical development program in transplantation. Despite the under-expanded development, FTY720 (0.5 mg) has been recently approved by the Food and Drug Administration as the primary oral treatment for multiple sclerosis (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fu-seaction=Search.DrugDetails). However, the authors felt that sharing the details of this study would be of value to the transplant community.

Materials and methods

Study design, patients and treatment

This was a 1-year, Phase III multicenter (14 centers across Europe and USA) randomized study followed by a 2-year on or off treatment.

Patients (18–65 years) who received a primary cadaveric or primary non-human leucocyte antigen matched living donor renal transplant and enrolled between April 2004 and April 2005 were randomized (1:1) to receive a pre-transplant priming dose of 5.0 mg FTY720 or 1.0 g MMF. After transplantation, FTY720 and MMF pre-treated patients received a single dose of 2.5 mg FTY720 or 2.0 g MMF divided into two daily doses, both in combination with tacrolimus 0.05 mg/kg/day (target whole blood trough levels, 1 month: 10–15 ng/mL; months 1–12: 5–12 ng/mL) and steroids according to each center’s standard practice (prednisone tapered not <5 mg), respectively.

The study conformed to the ethics and principles of the Declaration of Helsinki, Good Clinical Practice guidelines and local regulatory requirements, including institutional review board approval (ClinicalTrials.gov Identifier: NCT00239876). All patients gave written informed consent.

Assessments and statistical analysis

Primary efficacy outcome was the composite of treated biopsy-proven acute rejection (tBPAR), graft loss, death or premature study discontinuation within 6 months post-transplantation. Safety assessments were done during all or planned visits. Two protocol amendments for evaluating macular edema and bronchodilator reversibility testing were made within 1 year from the start of study.

Since the study was prematurely discontinued, confirmatory statistical analysis for non-inferiority was not done and only descriptive comparisons were made. P-values were generated for composite endpoint and values <0.05 were considered statistically significant.

Results

Of the 103 patients (predominantly male and Caucasian) randomized to FTY720 (n = 49) and MMF (n = 54), 39 completed the study up to Month 12 and 4 patients entered the extension phase. After a median follow-up of 339 (0–547) days, the premature discontinuations were higher in the FTY720 versus the MMF arm (37 versus 29) mainly due to the decision to stop the study (16 versus 21) and due to adverse events (AEs) (11 versus 2).

FTY720-based immunosuppressive regimen versus MMF was associated with numerically greater incidence of tBPAR (22.9 versus 18.5%, P = 0.476; Table 1). Banff Types IIA and IA were the most commonly reported biopsy-proven acute rejection (BPAR) grade for both treatments (Table 2). Neither of the treatment arms reported a significant cluster of cases at either extreme of the Banff scale, although accurate comparison between treatments is difficult due to the differing median exposure [at >450 days all of the FTY720-treated patients discontinued with the study and very few (5.6%) treated with MMF continued]. The Kaplan–Meier estimates for composite endpoint and illustrates consistently poorer results in the FTY720 versus MMF arm throughout the study, as rejections occurred earlier after transplantation in the FTY720 arm (Figure 1). Nevertheless, the proportion of patients discontinuing within 6 months post-transplantation were comparable for the treatment groups (12.5 versus 11.1%).

Respective overall incidence of AEs/serious adverse events (SAEs)/drug-related AEs (100/65.3/44.9 versus 98.1/66.7/46.3%) were similar with FTY720 and MMF. Infections AEs/SAEs were more frequent with MMF versus FTY720 [70.4/33.3 versus 51.0/14.3%, respectively (Table 3)]. Gastrointestinal AEs affected more patients on MMF (72.2 versus 61.2%), predominantly diarrhoea—a
common AE with MMF treatment. Discontinuations due to AEs were higher in the FTY720 versus the MMF arm (22.9 versus 3.7%).

Sixteen patients (32.7%) in the FTY720 arm and nine (16.7%) patients in the MMF arm reported ophthalmic AEs. Macular edema was reported in six patients in the FTY720 arm (12.2%) and five in the MMF arm (9.3%). However, patients with risk factors (diabetes, diabetic retinopathy, retinal vascular disease, past ocular surgery and uveitis) for macular edema were higher in the FTY720 versus the MMF arm (57.1 versus 50.0%). Follow-up evaluations were not available in any of these cases. Three (6.1%) patients on FTY720 and none on MMF had blurring of vision.

With both treatments, a transient decrease in heart rate was reported as an AE (FTY720: $n = 8$, 16.3%; MMF: $n = 1$, 1.9%) and events were not clinically manifested as SAEs. Systolic and diastolic blood pressure was not affected.

Decrease in lymphocytes on Day 1 with both treatments recovered on Day 7 in the MMF treatment arm but remained <30% of the baseline value in the FTY720 arm—as would be expected from its known mechanism of action [6]. No serious or severe pulmonary/respiratory events were reported. Mean creatinine clearance (Cockcroft–Gault) at end-of-treatment [FTY720: 273.5 (27–439) days, $n = 46$; MMF: 322 (67–469) days, $n = 52$] was 62 mL/min in the FTY720 arm and 64 mL/min in the MMF arm. Renal/graft function (serum creatinine and creatinine clearance) was preserved in the patients who were treated for BPAR while continuing study drug (Supplementary table 1). One patient in each treatment arm had malignancy as AE—prostatic carcinoma (MMF) and T-cell lymphoma (FTY720).

**Discussion**

The confounding effect of study discontinuation precludes firm conclusions about the efficacy and safety of FTY720 in renal transplant recipients; however, the incidence of tBPAR was higher in the FTY720 arm. FTY720-treated patients experienced fewer infections and gastrointestinal complications, whereas MMF-treated patients experienced fewer eye, respiratory and thoracic disorders. Increased incidences of macular edema and a transient decrease in heart rate of renal transplant patients treated with 2.5 mg FTY720 observed in this study has been reported in other transplant studies [7–9].

In conclusion, FTY720 combined with tacrolimus in de novo renal transplant recipients demonstrated no significant
therapeutic advantage and no significant advantage in AEs or SAEs compared to MMF-based standard treatment regimens. Renal function post-transplantation was comparable in both arms and FTY720-treated patients and FTY720 was associated with lower infection rates than MMF-treated patients.

Supplementary data

Supplementary table 1 is available online at http://ndt.oxfordjournals.org.

Acknowledgements. Akyol M, University of Edinburgh, Scotland, UK; Connolly JK, Belfast City Hospital; Belfast, Ireland; Dudley CRK, Southmed General Hospital, Bristol, Glyda MM, Wojewodzki Szpital Zespolony, Poland; Hariharon S, Medical College of Wisconsin, Wisconsin; Hyes DH, Carolinas Medical Center, NC, USA; Klinger M, Wroclaw Medical University, Poland; Leon JP, Lifelink Transplant Institute, FL, USA; Nicholson ML, University of Leicester; Leicester, UK; Washburn Jr WK,UTHSCSA, TX, USA.

Authors also thank, Vijay Singh, Ph. D., Novartis Pharma, India for involvement in data interpretation, medical writing, editorial assistance and for assistance in collating author comments.

Funding. The study was funded and supported by Novartis Pharma AG, Basel.

Conflict of interest statement. A.J.H., D.A. and Y.V. have no competing interest. E.S.W. received research grant, honoraria and travel grants from Novartis. P.P. is an employee of Novartis.

References


Received for publication: 22.11.10; Accepted in revised form: 25.7.11

Preliminary Communication

Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans

Barry I. Freedman1, Carl D. Langefeld2, Mariana Murea1, Lijun Ma1, James D. Otvos3, JoLyn Turner1, Peter A. Antinozzi4, Jasmin Divers2, Pamela J. Hicks4, Donald W. Bowden4, Michael V. Rocco1 and John S. Parks4,5

1Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3LipoScience, Inc., Raleigh, NC, USA; 4Department of Biochemistry and Centers for Diabetes Research and Human Genetics, Wake Forest School of Medicine, Winston-Salem, NC, USA and 5Department of Pathology - Lipid Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA

Correspondence and offprint requests to: Barry I. Freedman; E-mail: bfreedma@wakehealth.edu

Abstract

Background. Coding variants in the apolipoprotein L1 gene (APOL1) are strongly associated with non-diabetic nephropathy in African Americans. ApoL1 proteins associate with high-density lipoprotein (HDL) particles in the circulation. Plasma HDL particle subclass concentrations were compared in 73 African Americans based on APOL1 genotypes to detect differences potentially contributing to renal disease.

Methods. HDL subclass concentrations were measured using nuclear magnetic resonance spectroscopy in African American first-degree relatives of patients with non-diabetic end-stage renal disease. Participants had estimated glomerular filtration rates (GFRs) >